View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. Comment
December 15, 2020

Burden of pancreatic cancer is higher in Japan than other markets

By GlobalData Healthcare

Japan has an unusually high burden of pancreatic cancer. GlobalData epidemiologist forecast that this cancer burden will continue to rise in Japan in the next ten years despite the decrease in the Japanese population. GlobalData epidemiologists forecast an increase in diagnosed incident cases of pancreatic cancer in Japan from 42,000 cases in 2019 to 48,000 cases in 2029, at an annual growth rate (AGR) of 1.50%.

Free Report
img

What is the Global Healthcare and Pharma Market Q2 Outlook?

Given the background of high inflation, re-emerging supply chain issues, and the widespread macro-economic implications of the Ukraine conflict, the global pharmaceutical industry is facing an entirely new set of challenges following the turbulence of the COVID-19 pandemic. GlobalData’s World Markets Healthcare (WMH) service has released its latest Q2 forecast. This report incorporates the latest thinking on the opportunities and risks this new environment presents for pharma companies. However, the pharma sector is proving resilient, and we are projecting 4.4% global growth for the year ahead. Yet it remains that the current economic picture is inverting some baseline assumptions from previous quarterly forecasts and altering which markets we expect the key growth levers to derive from. Download our latest executive summary for a snapshot view of what our clients use to formulate winning strategies.
by GlobalData
Enter your details here to receive your free Report.

Incidence of pancreatic cancer in Japan has increased continuously over the past several decades. The incidence rate in Japan in 2019 as measured in cases per 100,000 population, was almost twice as high as in the US and 50% higher than in the 5EU (France, Germany, Italy, Spain, and the UK), and this trend will continue over the next ten years as shown in Figure 1.

The cause for the high incidence in Japan is unclear. While smoking, old age, and obesity are the strongest risk factors, the Japanese population is not at higher risk from obesity and smoking-related illnesses than the other markets. Age is a risk factor as Japan has an ageing population susceptible to this cancer. European countries are also experiencing demographic changes with ageing populations but do not have a similar incidence to Japan. It is possible that the Japanese population is more susceptible to the effects of pancreatic cancer risk factors than other populations.

The high rate of pancreatic cancer incidence in Japan is especially concerning because the disease is associated with high mortality. In Japan, this type of cancer is the fourth leading cause of cancer deaths. It is an aggressive disease where approximately 60%–80% of patients in Japan already have distant metastasis at presentation with a poor survival rate. Currently, an early diagnosis of pancreatic cancer is difficult due to the lack of clear diagnostic tools, which partly explains the low survival rate. Studies in Japan have reported that median survival for advanced-stage pancreatic cancer was just five months while it was more than one year for earlier stages, which implies that early diagnosis is key for better prognosis. The survival rates in other markets are comparable to Japan. In recent years, lots of research has been conducted into biomarkers such as PD-L1, BRCA, and PALB2, which will help to detect the disease earlier and predict the prognosis. These biomarkers could also shed light on why the Japanese population is more susceptible to pancreatic cancer.

Related Companies

Free Report
img

What is the Global Healthcare and Pharma Market Q2 Outlook?

Given the background of high inflation, re-emerging supply chain issues, and the widespread macro-economic implications of the Ukraine conflict, the global pharmaceutical industry is facing an entirely new set of challenges following the turbulence of the COVID-19 pandemic. GlobalData’s World Markets Healthcare (WMH) service has released its latest Q2 forecast. This report incorporates the latest thinking on the opportunities and risks this new environment presents for pharma companies. However, the pharma sector is proving resilient, and we are projecting 4.4% global growth for the year ahead. Yet it remains that the current economic picture is inverting some baseline assumptions from previous quarterly forecasts and altering which markets we expect the key growth levers to derive from. Download our latest executive summary for a snapshot view of what our clients use to formulate winning strategies.
by GlobalData
Enter your details here to receive your free Report.

Related Report
NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Pharmaceutical Technology